The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Clinical Trial Site, New York

Clinical Trial Site, New York

Clinical Trial Site, Taipei

Clinical Trial Site, Jacksonville

Clinical Trial Site, Columbus

Clinical Trial Site, Cologne

Clinical Trial Site, Joplin

Clinical Trial Site, Fort de France

Clinical Trial Site, Saint-Pierre

Clinical Trial Site, La Mesa

Clinical Trial Site, Aurora

Clinical Trial Site, Chicago

Clinical Trial Site, Baltimore

Clinical Trial Site, Boston

Clinical Trial Site, Detroit

Clinical Trial Site, Rochester

Clinical Trial Site, St Louis

Clinical Trial Site, Cooperstown

Clinical Trial Site, Buenos Aires

Clinical Trial Site, Westmead

Clinical Trial Site, Rio de Janeiro

Clinical Trial Site, São Paulo

Clinical Trial Site, Sofia

Clinical Trial Site, Vancouver

Clinical Trial Site, Nicosia

Clinical Trial Site, Créteil

Clinical Trial Site, Le Kremlin-Bicêtre

Clinical Trial Site, Lille

Clinical Trial Site, Marseille

Clinical Trial Site, Heidelberg

Clinical Trial Site, Münster

Clinical Trial Site, Pavia

Clinical Trial Site, Rome

Clinical Trial Site, Sicily

Clinical Trial Site, Ehime

Clinical Trial Site, Fukuoka

Clinical Trial Site, Hiroshima

Clinical Trial Site, Kumamoto

Clinical Trial Site, Nagano

Clinical Trial Site, Okawasuji

Clinical Trial Site, Ono

Clinical Trial Site, Ōita

Clinical Trial Site, Kuala Lumpur

Clinical Trial Site, Tlalpan

Clinical Trial Site, Groningen

Clinical Trial Site, Lisbon

Clinical Trial Site, Porto

Clinical Trial Site, Seoul

Clinical Trial Site, Barcelona

Clinical Trial Site, Huelva

Clinical Trial Site, Madrid

Clinical Trial Site, Palma de Mallorca

Clinical Trial Site, Umeå

Clinical Trial Site, Taipei

Clinical Trial Site, Istanbul

Clinical Trial Site, London